Sorafenib

Sorafenib tablets are a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma(1.1) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment (1.3) 1.1 Hepatocellular Carcinoma Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

12.1 Mechanism of Action Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC and DTC human tumor xenografts in immunocompromised mice.

Clinical clearance of Sorafenib (Kinase Inhibitor) relies on primary cyp3a4 cytochrome processing paired with glucuronide elimination for sorafenib with a Biphasic clearance with 5–13 hr terminal t½ under Sorafenib maintenance half-life; patients absorbing at Systemic oral bioavailability of roughly 65%–77% following first-pass transit bioavailability typically observe target onset around initial pharmacodynamic onset within 1–3 hrs (peak cmax) for sorafenib.

FDA clinical labeling for Sorafenib restricts administration in sorafenib tablets are contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of sorafenib tablets.; (4) sorafenib tablets in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. across 200 mg/1 Tablet, Film Coated, 400 mg, with self-reported patient tracking dominated by nausea (12.8% of reports), diarrhea (10.1% of reports), headache (7.6% of reports).